ID   SK-BR-3 shWDR12-4
AC   CVCL_YJ28
SY   SKBR-3 shWDR12-4
DR   cancercelllines; CVCL_YJ28
DR   Wikidata; Q98132643
RX   CelloPub=CLPUB00550;
CC   Population: Caucasian.
CC   Doubling time: 36-39 hours (CelloPub=CLPUB00550).
CC   Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12.
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 05-10-23; Version: 8
//
RX   CelloPub=CLPUB00550;
RA   Benhamron S.;
RT   "Validating WDR12 as a potential drug target in triple negative breast
RT   cancer.";
RL   Thesis MSc (2019), University of Toronto, Canada.
//